NASDAQ:OMER.O 8 January 2026

Omeros stock rises in premarket after $36,000-a-vial Yartemlea price is set

Omeros Corp shares rose about 4% to $14.09 premarket after setting a $36,000 price for each vial of newly approved Yartemlea, used to treat TA-TMA in transplant patients. The company began its U.S. launch Jan. 2 and reported $171.5 million in cash at year-end. Shares jumped 6.6% in after-hours trading Wednesday. Analysts raised price targets following the announcement.

8 January 2026

NASDAQ:OMER.O·Pharmaceuticals·Stock Market

GDS Holdings (GDS) Shares Surge Amid Mixed Valuation Signals
April 4, 2026, 4:32 PM EDT. GDS Holdings' share price has jumped 123.7% over three years but remains 49% below five-year levels, reflecting mixed investor sentiment. The stock recently slipped 1.2% in a week yet gained 4.1% year-to-date. A discounted cash flow (DCF) model warns the stock might be overvalued by a steep 6,640.7%, based on projected negative free cash flows turning positive only by 2030. Despite a high 61.47 price-to-earnings (P/E) ratio indicating strong growth expectations, GDS scores 0 out of 6 on valuation metrics, signaling potential risk. Investors reevaluate GDS's position amid its volatile returns, highlighting uncertainty about sustainable value amidst rapid price recovery.